# Peter MacCallum Cancer Centre, Australia: Phase 1 study withdrawn (Metastatic Castrate Resistant Prostate Cancer (mCRPC))

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Peter MacCallum Cancer Centre, Australia |
| Sponsor type | Academic and hospital |
| Study | Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer |
| NCT ID | NCT07090369 |
| Phase | Phase 1 |
| Status | withdrawn |
| Conditions | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
| Intervention types | drug, radiation |
| Site countries | Australia |
| Posted | 2025-07-29 |
| Planned start | 2025-11-01 |
| Event | Withdrawn before enrolling |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07090369). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.